[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:pancreatic-adenocarcinoma:circulating-tumor-derived-dna-negative":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Pancreatic Adenocarcinoma","Circulating Tumor-Derived DNA Negative",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07282912","Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels",[12],"Phase 2","RECRUITING","2026-08-26T02:19:29.119921Z","2026-05-05T02:43:28.285786Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05482516","Evaluating Novel Therapies in ctDNA Positive GI Cancers",[20],"Phase 3","2026-08-26T02:18:55.570428Z","2026-04-29T02:57:57.077131Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04616131","Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy",[],"2026-08-26T02:17:03.534765Z","2026-06-18T12:24:03.101835Z"]